C47 - Origins

[Jazzi]

::: Accessing Requested File :::
::: File Accessed \\ Input Authorisation Code :::
>> TEK395IO
::: Code Accepted \\ File Playback Commence :::

Subject: Phase Two - progress report
File: 095
Date: 803-02-13
Author: Dr. Gabriela Martez, Agency Nine. Project Lead.

The last of trial group four expired in the evening last cycle. This loss is regrettable; without the group's initial subjects there will need to be a cessation into the data being collected on the application of liquid cardamine. A requisition request for three hundred more subjects has been made. I harbour doubts as to how more subjects could be introduced into the habitat without breaking isolation protocols. One must try, however.

Perhaps this is for the best. Subjects administered liquid cardamine have consistently experienced extreme maleffects, often leading to swift transitions into psychosis. They speak of other worlds. Impossible structures, alien horizons, et cetera, before burning out. Strange... it occurs to me now how similar their rantings are. I shall arrange a review of the autopsies to evaluate for any commonalities in brain malformity.

As for the other experimental groups, results have been markedly more positive. Subjects within trial group two exhibitied a meteoric rise in productivity. Initially. Full of vitality and vigour, medical staff have extensively documented positive effects on health and wellbeing whilst simultaneously working longer shifts with greater output. This has been particularly true for those in the excavating and manufacturing cadres.

The cost of this boon made itself evident before long. So dependent did these subjects become to the substance that staff began to discover groups of subjects taking continual doses, hiding within the habitat and loosing themselves to the euphoric effects of the substance. I believe the term that subjects have been using is 'checking out'. On discussion, Commissar Karelin and I are agreed that intervention into this situation should not be made. We shall learn more about the longer-term effects of cardamine if we were to let the issue run it's course.

Trial group three is, perhaps, our most promising implementation of the substance. Subjects have reported elevated mood, function and productivity. Admittedly the nature of the tobcco-cardamine mix, where dosages are smaller, more drawn out and more frequent, have resulted in the magnitude of effect on subjects to be smaller. However, there have yet to be reports of any 'checking out' of trial group subjects. This is promising. If a sustainable 'high' can be facilitated then this form of intake may prove to be a more palatable and steady product to administer to the general workforce.

In light of these findings, I shall be proposing to the Commissar and the High Chancellor that we proceed into a modified phase three. Bring the internal control group into the active subject pool, place one third of those onto breather administration, and the rest onto the cardamine mix.

Doctor Martez

::: End File Playback :::